Flash Finance

Natco Pharma LimitedNATCOPHARMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹785.05
MCap ₹14,318 Cr · P/E 16.0
Natco Pharma Limited — Stock analysis & AI research Natco Pharma Limited — Multibagger AI analysis Natco Pharma Limited — Seasonality — best & worst months Natco Pharma Limited — Technical indicators & charts Natco Pharma Limited — Technical setup — score, trend, support & resistance Natco Pharma Limited — Double Top pattern broken down ↓ Natco Pharma Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 Small Cap Stocks List 📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹597 Cr
Sales · Jun 2026
-50.0% YoY
₹106 Cr
Operating Profit · Jun 2026
-80.4% YoY
17.8%
OPM % · Jun 2026
-60.7% YoY
₹75 Cr
Net Profit · Jun 2026
-83.9% YoY
₹4.17
EPS · Jun 2026
-83.9% YoY

📝 Natco Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Natco Pharma Limited reported revenue of ₹597 crore for the quarter ended June 2026 (Q1 FY27), down 50.0% from ₹1,193 crore in the same quarter last year, and down 2.0% sequentially over the March 2026 quarter.

Net profit fell 83.9% year-on-year to ₹75 crore, from ₹464 crore. Earnings per share (EPS) came in at ₹4.17.

Operating profit stood at ₹106 crore — an operating margin (OPM) of 17.8%, compared with 45.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Natco Pharma Limited posted revenue of ₹3,595 crore, a decline of 12.2% over FY25, with a net profit of ₹1,282 crore (down 30.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,999 crore with a net profit of ₹892 crore.

Valuation snapshot

At the current price of ₹785.05, NATCOPHARM has a market capitalisation of ₹14,318 crore and a trailing P/E of about 16.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 49.39%, foreign institutional investors (FIIs) 16.00%, domestic institutional investors (DIIs) 6.16%, public shareholders 28.45% of Natco Pharma Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹14,318 Cr
Current Price ?
₹785.0
P/E ?
16.04below ind
Industry P/E ?
35.00
P/B ?
1.67
P/S ?
4.77
P/FCF ?
10.29
Enterprise Value ?
₹15,027 Cr
EV/EBITDA ?
17.27
PEG ?
0.59
Earnings Yield ?
4.6%
Dividend Yield ?
0.77%
Profitability & Returns
Sales (TTM) ?
₹2,999 Cr
OPM ?
29.0%
Profit after tax (TTM) ?
₹892 Cr
EPS (TTM) ?
₹48.93
ROCE ?
17.0%
ROE ?
10.4%
ROA ?
8.7%
Growth
Sales — latest qtr ?
₹597 Cr
PAT — latest qtr ?
₹75 Cr
YoY qtr sales growth ?
-50.0%
YoY qtr profit growth ?
-83.9%
Sales growth (3y) ?
15%
Sales growth (5y) ?
17%
Profit growth (3y) ?
27%
Profit growth (5y) ?
35%
Financial Health
Debt ?
₹709 Cr
Debt to Equity ?
0.08
Interest Coverage ?
33.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.39%
Change in promoter holding ?
-0.17%
Pledged percentage ?
N/A
Market
Return 3 months ?
-16.9%
Return 6 months ?
-29.9%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 4137811,0489306259651,2371,2934081,1571,1931,264529609597 -50.0% -2.0%
Operating Profit 683285044422384537637912956154055212092106 -80.4% +15.2%
Other Income —18152530364051168626093557348 -19.5% -33.8%
Interest 313344433931281010 +220.0% -4.0%
Depreciation 383840404052404244945448424643 -20.9% -7.2%
Profit Before Tax 45306475424224432758797150521543586125110102 -81.2% -7.3%
Net Profit 3725440536019234963666112542846450110721075 -83.9% -64.5%
EPS 2.0413.9222.6320.1110.7219.4935.5336.916.9723.9025.9127.975.9711.704.17 -83.9% -64.4%
OPM % 16.5% 42.0% 48.1% 47.5% 38.1% 46.9% 61.7% 61.2% 7.1% 48.5% 45.3% 43.7% 22.7% 15.1% 17.8% -60.7% +17.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹4,095 Cr ₹3,595 Cr ₹2,999 Cr -12.2%
Operating Profit ₹2,144 Cr ₹1,304 Cr ₹870 Cr -39.2%
OPM % 52.36% 36.27% 29.01% -30.7%
NPM % 45.19% 35.66% 29.76% -21.1%
Other Income ₹321 Cr ₹281 Cr ₹269 Cr -12.5%
Depreciation ₹220 Cr ₹190 Cr ₹179 Cr -13.6%
Interest ₹19 Cr ₹33 Cr ₹40 Cr +73.7%
EBIT ₹1,924 Cr ₹1,114 Cr ₹691 Cr -42.1%
PBT ₹2,226 Cr ₹1,364 Cr ₹923 Cr -38.7%
Tax — — ₹27 Cr —
Net Profit ₹1,850 Cr ₹1,282 Cr ₹892 Cr -30.7%
EPS ₹103.31 ₹71.55 ₹49.81 -30.7%
Material Cost — — ₹158 Cr —
Employee Cost — — ₹151 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 36363636 +0.0%
Reserves 4,6665,5567,2988,517 +16.7%
Borrowings 161366275709 +157.8%
Other Liabilities 5255966611,026 +55.2%
Total Liabilities 5,3886,5548,27010,287 +24.4%
Fixed Assets 2,2342,2872,5172,615 +3.9%
CWIP 63134225293 +30.2%
Investments 6587428553,265 +281.9%
Other Assets 2,4343,3924,6734,114 -12.0%
Total Assets 5,3886,5548,27010,287 +24.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 7841,1961,6621,776 +6.9%
Cash from Investing Activity -437-960-1,444-2,078 -43.9%
Cash from Financing Activity -347-237-212302 +242.5%
Net Cash Flow 1-160 -100.0%
Free Cash Flow 6688621,2491,392 +11.4%
CFO/OP 110%88%94%164% +74.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 12311010577 -26.7%
Inventory Days 424379395460 +16.5%
Days Payable 126116138232 +68.1%
Cash Conversion Cycle 422373362305 -15.7%
Working Capital Days 213153149159 +6.7%
ROCE % 16%29%32%17% -46.9%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 49.56%49.48%49.48%49.41%49.39% -0.0%
FIIs 15.52%14.09%15.16%17.37%16.00% -7.9%
DIIs 5.81%5.87%5.39%5.46%6.16% +12.8%
Public 29.12%30.56%29.97%27.74%28.45% +2.6%
No. of Shareholders 4,29,4344,19,6994,24,1674,10,9704,04,135 -1.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 NATCOPHARM NATCO Pharma ₹816.50 14,891 13.3 3,484 1,083 30.2% 31.1% -7.9% -27.5% -44.7% -55.5%
❓ Frequently asked questions
What was Natco Pharma Limited's revenue in Q1 FY27?
Natco Pharma Limited reported revenue of ₹597 crore for the quarter ended June 2026 (Q1 FY27), down 50.0% from ₹1,193 crore in the same quarter last year, and down 2.0% sequentially over the March 2026 quarter.
What was Natco Pharma Limited's net profit in Q1 FY27?
Net profit fell 83.9% year-on-year to ₹75 crore, from ₹464 crore. Earnings per share (EPS) came in at ₹4.17.
What is NATCOPHARM's market capitalisation and P/E ratio?
At the current price of ₹785.05, NATCOPHARM has a market capitalisation of ₹14,318 crore and a trailing P/E of about 16.0.
Who owns Natco Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 49.39%, foreign institutional investors (FIIs) 16.00%, domestic institutional investors (DIIs) 6.16%, public shareholders 28.45% of Natco Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI